Pharmaceutical and biotechnology company Symbiotec Pharmalab has raised Rs 526.20 crore from anchor investors ahead of its initial public offering (IPO), which opens for public subscription on August 24, 2026. Through the public issue, the company seeks to raise Rs 1,757 crore.
The company said it has finalised the allocation of 53,25,909 equity shares to anchor investors at an anchor investor allocation price of Rs 988 per share, including a share premium of Rs 986 per share, aggregating to Rs 526.20 crore. Of the total anchor investor portion, 40% was reserved for domestic mutual funds, life insurance companies and pension funds. Of this, 33.33% was reserved for domestic mutual funds, while 6.67% was reserved for life insurance companies and pension funds.
